Augmentin 500 mg Dosing for Adults
For most adult infections, Augmentin 500 mg should be dosed as 500 mg/125 mg three times daily (every 8 hours) for 7-10 days, though the 875 mg/125 mg twice daily (every 12 hours) formulation is equally effective and may improve compliance. 1, 2, 3
Standard Dosing Regimens
Available Formulations and Indications
Community-Acquired Pneumonia (CAP) with Comorbidities:
- Amoxicillin/clavulanate 875 mg/125 mg twice daily OR
- Amoxicillin/clavulanate 500 mg/125 mg three times daily
- Combine with a macrolide (azithromycin or clarithromycin) or doxycycline 4, 5
- Duration: Typically 5-7 days for CAP 5
Acute Bacterial Rhinosinusitis (ABRS):
- Standard dose: 500 mg/125 mg three times daily for 5-10 days 6
- High-dose regimen (for resistant organisms): 2000 mg/125 mg twice daily 6, 7
- Use high-dose if: recent antibiotic use (past 4-6 weeks), moderate-to-severe infection, age >65 years, diabetes, immunocompromised, or high local resistance rates 6, 7
Lower Respiratory Tract Infections:
- 875 mg/125 mg twice daily is as effective as 500 mg/125 mg three times daily 3
- Duration: 7-15 days depending on severity 3
- The twice-daily regimen may have less diarrhea 3
Key Clinical Considerations
When to Use High-Dose Amoxicillin/Clavulanate
The 2000 mg/125 mg twice daily regimen should be considered when 6, 7:
- Antibiotic use within the past month
- Moderate to severe symptoms or protracted illness
- Frontal or sphenoidal sinusitis
- Age >65 years
- Comorbidities (diabetes, chronic cardiac/hepatic/renal disease)
- Immunocompromised status
- High prevalence of penicillin-resistant S. pneumoniae in community (>10%)
- Close contact with daycare facilities or healthcare environments
Comparative Efficacy: 875 mg BID vs 500 mg TID
Both regimens are clinically equivalent for most infections 2, 3. A 1998 study of 170 patients with acute bacterial sinusitis showed clinical success rates of 93% (875 mg BID) vs 88% (500 mg TID), with no significant difference (P=0.76) 2. Similarly, a 1997 study of 557 patients with lower respiratory tract infections demonstrated 93% vs 94% clinical success rates respectively 3.
The 875 mg twice-daily formulation offers:
- Improved compliance (fewer daily doses)
- Potentially less moderate-to-severe diarrhea 3
- Equivalent bacteriologic eradication rates 2, 3
Recent Evidence on Amoxicillin vs Amoxicillin/Clavulanate
A 2026 observational study of 234,608 adults with acute sinusitis found no difference in treatment failure between amoxicillin/clavulanate 875/125 mg BID and amoxicillin 875 mg BID (3.0% vs 3.1%; RR 0.96) 8. However, amoxicillin/clavulanate was associated with higher rates of yeast infections (1.1% vs 0.8%) and C. difficile infections (0.04% vs 0.02%) 8.
This suggests amoxicillin alone may be preferred for uncomplicated sinusitis in adults without risk factors for resistant organisms 8, reserving amoxicillin/clavulanate for patients with comorbidities or recent antibiotic exposure 4, 6.
Administration Guidelines
- Take at the start of meals to minimize gastrointestinal intolerance and enhance clavulanate absorption 1
- Reconstituted suspension stable for 10 days under refrigeration 1
- Adjust dose in renal impairment 9
Duration of Therapy
Shorter courses are preferred when appropriate 6:
- ABRS: 5-10 days (most trials use 10 days) 6
- CAP: 5-7 days typically sufficient 5
- Lower respiratory tract infections: 7-15 days 3
- Postoperative prophylaxis (facial fractures): ≤24 hours is sufficient 10
Common Pitfalls to Avoid
Do not substitute different Augmentin formulations interchangeably - the clavulanate content varies significantly between suspensions 1
Do not use for viral infections - contributes to resistance without benefit 6
Do not prescribe macrolides or TMP-SMX as first-line for sinusitis - high resistance rates (>40% for macrolides, 50% for TMP-SMX against S. pneumoniae) 6
Avoid prolonged prophylaxis - increases adverse events without additional benefit 10
Consider amoxicillin alone first for uncomplicated sinusitis in patients without risk factors 8